>From Malcolm I was dx 7.7.04 and have been on 400mg Gleevec since dx. My response is excellent, my blood counts falling to normal within weeks of dx on Gleevec, and I hope my latest Bone Marrow test (results due soon) may been unable to detect any signs under PCR. My children are 13 & 11 and a year on from dx, I now want to tell them. Has anyone prepared a question and answer list or any advice on the types of questions they will ask?
-----Original Message----- From: [email protected] [mailto:[EMAIL PROTECTED] Sent: 12 June 2005 14:53 To: [email protected] Subject: [CML] Digest Number 4021 There are 15 messages in this issue. Topics in this digest: 1. Re: what does it all mean ???? From: char fisher <[EMAIL PROTECTED]> 2. Hematological malignancies: evolving the lifeblood of future pharmacotherapy From: "Rob" <[EMAIL PROTECTED]> 3. Relay participants walk to raise $115,000 From: "Rob" <[EMAIL PROTECTED]> 4. The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation From: "Rob" <[EMAIL PROTECTED]> 5. Rapid computational identification of the targets of protein kinase inhibitors From: "Rob" <[EMAIL PROTECTED]> 6. Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR. From: "Rob" <[EMAIL PROTECTED]> 7. Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphi From: "Rob" <[EMAIL PROTECTED]> 8. Study on the role of angiogenesis and related factors in leukemias From: "Rob" <[EMAIL PROTECTED]> 9. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib From: "Rob" <[EMAIL PROTECTED]> 10. Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development? From: "Rob" <[EMAIL PROTECTED]> 11. Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity From: "Rob" <[EMAIL PROTECTED]> 12. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. From: "Rob" <[EMAIL PROTECTED]> 13. CML and Prostate Cancer From: Richard Troxel <[EMAIL PROTECTED]> 14. Pic Of The Day | June 12, 2005 From: "Rob" <[EMAIL PROTECTED]> 15. Daily Quotation | June 12, 2005 From: "[EMAIL PROTECTED]" <[EMAIL PROTECTED]> ________________________________________________________________________ ________________________________________________________________________ Message: 1 Date: Sat, 11 Jun 2005 11:29:41 -0700 (PDT) From: char fisher <[EMAIL PROTECTED]> Subject: Re: what does it all mean ???? Thank you rob :) Ive been on 400mg for the last 6 months. Char :) :) :) Rob <[EMAIL PROTECTED]> wrote: It can fluctuate. What dose have you been on? Rob ----- Original Message ----- From: char fisher To: cml group Sent: Saturday, June 11, 2005 12:42 AM Subject: [CML] what does it all mean ???? I got a call from my dr. today saying my fish went up. In Dec. when i first found out about the leukemia it was 96%, In March my FISH was 34% now its up to 45 %. I dont understand ???? Its been 6 months .... should I have a tolerence to gleevec this early ? Does this mean that when they up me to 800mg it may not hold long ??? Im so scared and confused. Char :) --------------------------------- Discover Yahoo! Find restaurants, movies, travel & more fun for the weekend. Check it out! New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML --------------------------------- Yahoo! Groups Links To visit your group on the web, go to: http://groups.yahoo.com/group/CML/ To unsubscribe from this group, send an email to: [EMAIL PROTECTED] Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service. --------------------------------- Discover Yahoo! Have fun online with music videos, cool games, IM & more. Check it out! [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 2 Date: Sat, 11 Jun 2005 21:45:24 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Hematological malignancies: evolving the lifeblood of future pharmacotherapy Hailed as a beacon for the future of cancer drug development when it was launched in May 2001, Novartis's Glivec has achieved a dominant position in the chronic myeloid leukemia (CML) market and garnered worldwide sales of $1.6billion in 2004. However, while Glivec remains the gold standard treatment for CML, the emergence of Glivec drug resistance has left a void in the market. http://cmlsupport.blogspot.com/2005/06/hematological-malignancies-evolving.html [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 3 Date: Sat, 11 Jun 2005 21:46:27 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Relay participants walk to raise $115,000 Participants in Lewisburg's movie-themed Relay For Life were following the yellow brick road to find a cure for cancer and reach their goal of raising $115,000. Mark Speake and Jan Lewis, members of the Wizard of Oz team are participating in their third relay. http://cmlsupport.blogspot.com/2005/06/relay-participants-walk-to-raise.html [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 4 Date: Sat, 11 Jun 2005 21:57:39 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramolecular interactions between the SH3, SH2, and kinase (SH1) domains. We have determined the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail. This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe. http://cmlhope.com/?q=node/24 [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 5 Date: Sat, 11 Jun 2005 21:58:29 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Rapid computational identification of the targets of protein kinase inhibitors We describe a method for rapidly computing the relative affinities of an inhibitor for all individual members of a family of homologous receptors. The approach, implemented in a new program, SCR, models inhibitor-receptor interactions in full atomic detail with an empirical energy function and includes an explicit account of flexibility in homology-modeled receptors through sampling of libraries of side chain rotamers. SCR's general utility was demonstrated by application to seven different protein kinase inhibitors: for each inhibitor, relative binding affinities with panels of approximately 20 protein kinases were computed and compared with experimental data. http://cmlhope.com/?q=node/23 [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 6 Date: Sat, 11 Jun 2005 21:59:24 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR. To quantify bone marrow bcr/abl mRNA levels in imatinib mesylate treated Ph chromosome positive chronic myeloid leukemia (CML) patients. METHODS: Serial monitoring of bcr/abl mRNA levels by real-time quantitative RT-PCR technique (RQ-PCR) was performed in 34 cases (120 samples) of CML treated with imatinib mesylate. All the patients were IFNalpha based treatment failure before enrolled in this study and the percentage of Ph(+) bone marrow cells were over 95%. http://cmlhope.com/?q=node/22 [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 7 Date: Sat, 11 Jun 2005 22:00:08 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphi To investigate clonal evolution of abnormal Philadelphia chromosome-negative cells (Ph(-)CE) after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph(+)CML). http://cmlhope.com/?q=node/21 [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 8 Date: Sat, 11 Jun 2005 22:00:58 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Study on the role of angiogenesis and related factors in leukemias OBJECTIVE: To observe the bone marrow angiogenesis in leukemis and evaluate the expression and role of endostatin (ES), vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in leukemia patients. METHODS: Bone marrow angiogenesis was assayed by vWF immunohistochemical method. The ES and VEGF concentrations in plasma were detected by ELISA. The expression of VEGFR in leukemia cells was determined by flow cytometry (FCM). http://cmlhope.com/?q=node/20 [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 9 Date: Sat, 11 Jun 2005 22:04:37 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib Bornh�user M, Pursche S, Bonin M, Freiberg-Richter J, Jenke A, Illmer T, Ehninger G, Schleyer E J Clin Oncol. 2005 Jun 1; 23(16): 3855-6; author reply 3857-8 No abstract yet. http://cmlsupport.blogspot.com/2005/06/elimination-of-imatinib-mesylate-and.html [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 10 Date: Sat, 11 Jun 2005 22:05:49 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development? Breccia M, D'Andrea M, Alimena G Eur J Haematol. 2005 Jul ; 75(1): 89-90 No abstract yet. http://cmlsupport.blogspot.com/2005/06/can-nifedipine-and-estrogen.html [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 11 Date: Sat, 11 Jun 2005 22:07:07 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity Quinone oxidoreductases (NQO1 and NQO2) are cytosolic proteins that catalyze metabolic reduction of quinones and its derivatives to protect cells against redox cycling and oxidative stress. In humans, a high percentage of individuals with myeloid and other types of leukemia are homo- and heterozygous for a null mutant allele of NQO1. http://cmlsupport.blogspot.com/2005/06/quinone-oxidoreductases-in-protection.html [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 12 Date: Sat, 11 Jun 2005 22:08:09 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. The major cause of failure after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) is disease relapse or progression. We analyzed the outcome of second HSCT for treatment of patients with relapsed, refractory AML/myelodysplastic syndrome (MDS) at our institution. http://cmlsupport.blogspot.com/2005/06/disease-burden-may-identify-patients.html [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 13 Date: Sat, 11 Jun 2005 20:15:10 -0700 From: Richard Troxel <[EMAIL PROTECTED]> Subject: CML and Prostate Cancer I have been diagnosed with prostate cancer as the result of a biopsy taken a week ago. I'm 61 and was diagnosed with CML in 2/2003 and I've been on IM since 3/2003. Currently I'm PCRU. Prostate cancer is a common disease for men 60+ and is very successfully treated by any of a number of options. My type of PC is not particularly aggressive so waiting a few years would not ordinarily be out of the question. I do not believe the CML and PC are related except that my CML does complicate the decision process both from a personal and a medical standpoint. Has anyone had experience with both CML and PC? Does anyone know if radiation therapy and or hormone therapy would have an impact on my CML? My wife thinks that If I opt for surgery (complete removal of the prostate) that I should do so now while I am doing well with the CML rather than wait and risk having both CML and PC crises to deal with. Any thoughts? I see my CML oncologist this week and the radiation doctors next week to get their input. Would be great to have some really good questions to put to them. Richard Troxel ________________________________________________________________________ ________________________________________________________________________ Message: 14 Date: Sat, 11 Jun 2005 23:36:56 -0500 From: "Rob" <[EMAIL PROTECTED]> Subject: Pic Of The Day | June 12, 2005 Rough surf pounds the beach of the Gulf of Mexico as Tropical Storm Arlene churns offshore near Seagrove Beach, Florida. http://cmlsupport.blogspot.com/2005/06/pic-of-day_12.html [This message contained attachments] ________________________________________________________________________ ________________________________________________________________________ Message: 15 Date: Sun, 12 Jun 2005 01:01:31 -0500 From: "[EMAIL PROTECTED]" <[EMAIL PROTECTED]> Subject: Daily Quotation | June 12, 2005 June 12, 2005 Nothing is as dangerous as an ignorant friend; a wise enemy is to be prefered. Jean De La Fontaine Fables ________________________________________________________________________ ________________________________________________________________________ New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML ------------------------------------------------------------------------ Yahoo! Groups Links ------------------------------------------------------------------------ ------------------------ Yahoo! Groups Sponsor --------------------~--> Ever feel sad or cry for no reason at all? Depression. Narrated by Kate Hudson. http://us.click.yahoo.com/1visLB/esnJAA/xGEGAA/8zSolB/TM --------------------------------------------------------------------~-> New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links <*> To visit your group on the web, go to: http://groups.yahoo.com/group/CML/ <*> To unsubscribe from this group, send an email to: [EMAIL PROTECTED] <*> Your use of Yahoo! Groups is subject to: http://docs.yahoo.com/info/terms/
